Figure 2.
Figure 2. NOD HSCs engraft in B10.BR recipients in the presence of equal numbers of B10.BR HSCs. The ability of NOD HSCs to engraft in allogeneic B10.BR recipients was assessed using a modified competitive reconstitution assay.21-23 (A) Percent engraftment of B10.BR mice given 10 000 NOD KSL cells in the presence of increasing numbers of B10.BR KSL cells. Groups shown are: no B10.BR KSL cells (n = 12); 1000 B10.BR KSL cells (n = 8); 2000 B10.BR KSL cells (n = 4); 5000 B10.BR KSL cells (n = 3); and 10 000 B10.BR KSL cells (n = 13). (B) The kinetics of allogeneic chimerism in the engrafting B10.BR mice are shown based on the number of B10.BR KSL cells coadministered with the 10 000 NOD KSL cells (▵ represents none; □, 1 × 103; ○, 2 × 103; ▴, 5 × 103; and ▪, 10 × 103).

NOD HSCs engraft in B10.BR recipients in the presence of equal numbers of B10.BR HSCs. The ability of NOD HSCs to engraft in allogeneic B10.BR recipients was assessed using a modified competitive reconstitution assay.21-23  (A) Percent engraftment of B10.BR mice given 10 000 NOD KSL cells in the presence of increasing numbers of B10.BR KSL cells. Groups shown are: no B10.BR KSL cells (n = 12); 1000 B10.BR KSL cells (n = 8); 2000 B10.BR KSL cells (n = 4); 5000 B10.BR KSL cells (n = 3); and 10 000 B10.BR KSL cells (n = 13). (B) The kinetics of allogeneic chimerism in the engrafting B10.BR mice are shown based on the number of B10.BR KSL cells coadministered with the 10 000 NOD KSL cells (▵ represents none; □, 1 × 103; ○, 2 × 103; ▴, 5 × 103; and ▪, 10 × 103).

Close Modal

or Create an Account

Close Modal
Close Modal